Healthcare workers had acceptable preparedness during first COVID-19 wave
Dec 30, 2021
Female healthcare workers, however, had lower preparedness and awareness scores than male counterparts.
CDC lowers estimate of omicron prevalence in the United States
Dec 29, 2021
Predictions are likely to become more accurate as researchers learn more about omicron.
Alterations in gut microbiome ID’d in postacute COVID-19 syndrome
Jan 27, 2022
Higher levels of Ruminococcus gnavus, Bacteroides vulgatus, and lower levels of Faecalibacterium prausnitzii were observed in patients with PACS.
mRNA COVID-19 efficacy lower for immunocompromised adults
Nov 04, 2021
Vaccine effectiveness of two doses of mRNA vaccine lower against COVID-19-associated hospitalization, with variation by condition. mRNA vaccines approved to fight COVID-19 in the U.S. include Pfizer-BioNTech...
New data show the power of COVID-19 vaccines
Aug 02, 2021
Data support what health experts have been saying for months: COVID-19 vaccines are highly effective at preventing serious illness and death.
Odds of hospitalization lower with remote monitoring in COVID-19
Jul 26, 2022
Shorter length of stay and less intensive care use were reported with activation of a remote patient monitoring program.
Odds of COVID-19 hospitalization lower after vaccination
Sep 02, 2021
Compared with infected unvaccinated individuals, infected vaccinated individuals report almost all symptoms less frequently.
Omicron linked to increase in COVID-19 cases, lower disease severity
Jan 27, 2022
The mean length of stay and percentages admitted to the ICU, receiving invasive mechanical ventilation and dying were lower during omicron.
CDC: Vaccinated more likely to die during omicron wave if they got J&J shot
Mar 25, 2022
However, breakthrough infections among J&J vaccine recipients were similar or lower compared with the other vaccines.
Risk for progression to severe COVID-19 lower with nirmatrelvir + ritonavir
Mar 01, 2022
Treatment of symptomatic COVID-19 with nirmatrelvir plus ritonavir was linked to an 89% lower risk for progression versus placebo.